Blood, 15 October 2001, Vol. 98, No. 8, pp. 2291-2291
Leukemia stem cells and constitutive activation
of NF-
B
It has been clear for many years that leukemic cells
from most patients with AML are organized into a hierarchy reminiscent of normal hematopoiesis. The disease is thought to originate in leukemic stem cells, characterized by an immature phenotype and possessing self-renewal capacity. This hierarchy was probably first
appreciated when it was discovered that only a small subset of AML
cells can form colonies in vitro, and later more elegantly documented
by showing that only leukemic cells with a primitive immunophenotype
can generate leukemia upon transfer into NOD/SCID mice. Since these
stem cells, like normal stem cells, are relatively quiescent, it has
been thought that they contribute substantially to drug
resistance and thus to relapse. Therefore, in this era of targeted
therapy, identification of biochemical and molecular features that
distinguish leukemic stem cells from normal stem cells may be important
in the design of the next generation of AML therapies.
Guzman and colleagues (page 2301) show that cells with a "stem cell
phenotype" from the blood of patients with AML have constitutive activation of the NF-
B transcription factor complex; cells with a
similar immunophenotype from normal marrow or cord blood do not.
Further, leukemic, but not normal, CD34+ cells
underwent apoptosis when treated with a proteosome inhibitor, MG-132,
that blocks NF-B activity (among other things). Although it has
previously been reported that AML cells (and many other types of
hematopoietic neoplasms) have constitutive activation of NF-B and
that AML cells are sensitive to MG-132, this is the first demonstration
that activation of NF-B is a major distinguishing characteristic
between normal and leukemic stem cells. If selective killing of
leukemic cells through inhibition of NF-B can be verified in vivo,
then this pathway may prove to be a fruitful one for drug discovery.
Whether proteosome inhibition is the best way to inhibit NF-B, or
conversely whether the toxic effects of MG-132 are actually due to
inhibition of NF-B, remains to be determined. Other questions are
also raised. Why is NF-B activated in virtually all cases of AML? In
normal cells, NF-B is induced by diverse stimuli, such as growth
factors, or as a cytoprotective response to toxic events. In leukemic
cells, is increased NF-B activity due to upstream signals from
proviability oncogenes such as ras or FLT3? Or is NF-B
induced by the cell to counteract some of the toxic effects of an
oncogene such as myc? In the long run, the best way to inhibit NF-B
may well be to inhibit the activity of the oncogene that induces it.
Finally, inhibition of NF-B could have an indirect benefit in AML
therapy. Inhibition of NF-B has been shown to enhance
sensitivity of several epithelial cancers to standard chemotherapy
drugs, and it may therefore be possible to increase the therapeutic
index of existing AML drugs without causing additional damage to normal
stem cells.
James D. Griffin
Dana-Farber Cancer Institute
